BriaCell Therapeutics Corp. (TSE:BCT – Free Report) – Research analysts at HC Wainwright issued their FY2029 earnings estimates for shares of BriaCell Therapeutics in a research report issued on Thursday, September 19th. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings of ($0.07) per share for the year.
BriaCell Therapeutics Price Performance
Shares of TSE:BCT opened at C$0.88 on Friday. The company has a market capitalization of C$16.09 million, a price-to-earnings ratio of -1.76 and a beta of 1.74. BriaCell Therapeutics has a 1 year low of C$0.64 and a 1 year high of C$8.65. The business’s 50-day moving average is C$0.95 and its 200-day moving average is C$2.08.
About BriaCell Therapeutics
BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.
See Also
- Five stocks we like better than BriaCell Therapeutics
- Stock Market Upgrades: What Are They?
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- What is a Secondary Public Offering? What Investors Need to Know
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- What is a Stock Market Index and How Do You Use Them?
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
